All sponsors

Octapharma

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-36
RECRUITING5
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO83%

Delay Index: of 6 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +29.0 months). See all sponsors →

Open Octapharma on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Newnorm
NCT04640142
P3Active, not recruitingPrimary Immune Deficiency502026-11 (+64 mo)
OCTA-C1-INH
NCT06361537
P3RecruitingAcute Hereditary Angio Edema1242026-12 (+12 mo)
Atenativ
NCT04918173
P3RecruitingCongenital Antithrombin Deficiency382026-12-01 (+29 mo)
Human plasma derived antithrombin
NCT06096116
P3RecruitingAcquired Antithrombin Deficiency1202028-03 (+18 mo)
Panzyga
NCT04929236
P3RecruitingPediatric Chronic Inflammatory Demyelinating Polyneuropathy302028-12-31 (+43 mo)
Panzyga, 10% Intravenous Solution
NCT07220915
P3RecruitingHypogammaglobulinemia; Autoimmune Conditions3602029-12